SCHEMBL17257560

SCHEMBL17257560

CC(=NOCc1ccccc1)c1ccc(C#N)cc1

nearest known ligand 0.89

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.89
RAB9A P51151 4/20 0.89
SMN1; SMN2 Q16637 2/20 0.89
L3MBTL1 Q9Y468 2/20 0.89
MAPT P10636 1/20 0.58
MAOB P27338 1/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HTT P42858 2/20 0.50
LMNA P02545 2/20 0.50
GAA P10253 1/20 0.50
MAPK1 P28482 1/20 0.50
S1PR1 P21453 2/20 0.47
PPARG P37231 2/20 0.44
PPARA Q07869 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17257559 1.00 NPC1 (0.89) NPC1RAB9ASMN1; SMN2L3MBTL1MAPT
Water SCHEMBL4316877 0.86 NPC1 (0.74) NPC1RAB9ASMN1; SMN2L3MBTL1HTT
SCHEMBL7672573 0.85 NPC1 (0.73) NPC1RAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL7672574 0.85 NPC1 (0.73) NPC1RAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL4451421 0.84 L3MBTL1 (0.71) NPC1RAB9ASMN1; SMN2L3MBTL1HTT
SCHEMBL19733323 0.84 L3MBTL1 (0.71) NPC1RAB9ASMN1; SMN2L3MBTL1HTT
SCHEMBL17257319 0.84 NPC1 (0.68) NPC1RAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL5958128 0.80 NPC1 (0.62) NPC1RAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL12260710 0.80 NPC1 (0.58) NPC1RAB9ASMN1; SMN2L3MBTL1HTT
SCHEMBL5958131 0.80 NPC1 (0.62) NPC1RAB9ASMN1; SMN2L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US claimed
EP-3143055-A2 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP Bridgestone Corporation (JP) 2017-03-22 EP claimed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US claimed
WO-2015175280-A2 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 WO claimed
EP-3143055-B1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORP (JP) 2019-09-04 EP disclosed
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US disclosed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group PAM, PPOX, MB NPC1 4775/4885RAB9A 4587/4885SMN1; SMN2 716/4885
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP PAM, PPOX, MB NPC1 4775/4885RAB9A 4587/4885SMN1; SMN2 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.